home / stock / imv:cc / imv:cc quote
Last: | $0.63 |
---|---|
Change Percent: | 1.61% |
Open: | $0.62 |
Close: | $0.62 |
High: | $0.64 |
Low: | $0.6 |
Volume: | 19,616 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.63 | $0.62 | $0.62 | $0.64 | $0.6 | 19,616 | 08-02-2022 |
$1.4 | $1.45 | $1.4 | $1.45 | $1.4 | 22,751 | 05-06-2022 |
$1.41 | $1.38 | $1.41 | $1.44 | $1.38 | 68,488 | 05-05-2022 |
$1.41 | $1.54 | $1.41 | $1.57 | $1.39 | 137,321 | 05-04-2022 |
$1.51 | $1.52 | $1.51 | $1.55 | $1.5 | 40,371 | 05-03-2022 |
$1.52 | $1.59 | $1.52 | $1.59 | $1.52 | 12,581 | 05-02-2022 |
$1.58 | $1.55 | $1.58 | $1.58 | $1.54 | 23,482 | 04-29-2022 |
$1.57 | $ | $1.57 | $1.64 | $1.54 | 14,014 | 04-28-2022 |
$1.57 | $1.58 | $1.57 | $1.64 | $1.57 | 19,892 | 04-27-2022 |
$1.58 | $1.51 | $1.58 | $1.62 | $1.51 | 44,201 | 04-26-2022 |
$1.56 | $1.51 | $1.56 | $1.56 | $1.51 | 18,424 | 04-25-2022 |
$1.57 | $1.49 | $1.57 | $1.58 | $1.49 | 28,777 | 04-22-2022 |
$1.51 | $1.65 | $1.51 | $1.65 | $1.51 | 63,797 | 04-21-2022 |
$1.65 | $1.66 | $1.65 | $1.69 | $1.6 | 44,047 | 04-20-2022 |
$1.67 | $1.72 | $1.67 | $1.72 | $1.6 | 38,724 | 04-19-2022 |
$1.72 | $1.72 | $1.72 | $1.77 | $1.67 | 120,538 | 04-18-2022 |
$1.72 | $1.75 | $1.72 | $1.77 | $1.7 | 49,419 | 04-15-2022 |
$1.72 | $1.75 | $1.72 | $1.77 | $1.7 | 49,419 | 04-14-2022 |
$1.71 | $1.8 | $1.71 | $1.82 | $1.71 | 78,131 | 04-13-2022 |
$1.78 | $1.8 | $1.78 | $1.82 | $1.77 | 27,482 | 04-12-2022 |
News, Short Squeeze, Breakout and More Instantly...
Imv Inc. Company Name:
IMV:CC Stock Symbol:
TSXC Market:
IMV Inc. (the “ Company ” or “ IMV ”) announces today that it has accepted an offer (the “ Offer ”) from IMV’s largest secured creditors (the “ Secured Lenders ”), pursuant to which IMV and its subsidiary, Immunovaccin...
IMV Inc. (the “ Company ” or “ IMV ”), recently announced an update on the Sales and Investment Solicitation Process (the “ SISP ”) implemented as part of its ongoing proceedings under the Companies' Creditors Arrangement Act (the “...
IMV Inc. (the “ Company ” or “ IMV ”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced tha...